ECSP045297A - MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFN? - Google Patents

MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFN?

Info

Publication number
ECSP045297A
ECSP045297A EC2004005297A ECSP045297A ECSP045297A EC SP045297 A ECSP045297 A EC SP045297A EC 2004005297 A EC2004005297 A EC 2004005297A EC SP045297 A ECSP045297 A EC SP045297A EC SP045297 A ECSP045297 A EC SP045297A
Authority
EC
Ecuador
Prior art keywords
inhibitors
microgly
interleucine
ifn
interrupt
Prior art date
Application number
EC2004005297A
Other languages
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045297A publication Critical patent/ECSP045297A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere al uso de inhibidores de la microglía para preparar fármacos que inhiben las reacciones inmunes asociadas con monocitos, macrófagos y células-T y a su uso para el tratamiento de enfermedades inmunológicas asociadas con células-T y reacciones inflamatorias no asociadas con células-T.The invention relates to the use of microglia inhibitors to prepare drugs that inhibit the immune reactions associated with monocytes, macrophages and T-cells and their use for the treatment of immunological diseases associated with T-cells and inflammatory reactions not associated with cells. T.

EC2004005297A 2002-02-15 2004-09-14 MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFN? ECSP045297A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (en) 2002-02-15 2002-02-15 Microlia inhibitors for interruption of interleukin 12 and IFN-gamma mediated immune responses

Publications (1)

Publication Number Publication Date
ECSP045297A true ECSP045297A (en) 2004-10-26

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005297A ECSP045297A (en) 2002-02-15 2004-09-14 MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFN?

Country Status (21)

Country Link
EP (1) EP1474138A1 (en)
JP (1) JP2005522447A (en)
KR (1) KR20040084909A (en)
CN (1) CN1756546A (en)
AR (1) AR039556A1 (en)
AU (1) AU2003245523A1 (en)
BR (1) BR0307706A (en)
CA (1) CA2475770A1 (en)
DE (1) DE10207843A1 (en)
EC (1) ECSP045297A (en)
MX (1) MXPA04007943A (en)
NO (1) NO20043840L (en)
PE (1) PE20030906A1 (en)
PL (1) PL371327A1 (en)
RS (1) RS71304A (en)
RU (1) RU2004127677A (en)
TW (1) TW200306823A (en)
UA (1) UA81111C2 (en)
UY (1) UY27662A1 (en)
WO (1) WO2003068225A1 (en)
ZA (1) ZA200407382B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (en) * 2002-02-15 2003-09-04 Schering Ag 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing these derivatives
ES2334924T3 (en) * 2005-03-17 2010-03-17 Proyecto De Biomedicina Cima, S.L. EMPLOYMENT OF 5'-METHYLTIOADENOSINE (MTA) IN THE PREVENTION AND / OR TREATMENT OF AUTOIMMUNE DISEASES AND / OR REJECTION OF TRANSPLANTS.
BR112014030940B1 (en) * 2012-06-11 2022-09-06 UCB Biopharma SRL BENZIMIDAZOLS THAT MODULATE TNF-ALFA AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
PT3371190T (en) 2015-11-06 2022-07-08 Incyte Corp Heterocyclic compounds as pi3k-gamma inhibitors
AU2016371598B2 (en) * 2015-12-15 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
KR102717072B1 (en) 2017-10-18 2024-10-15 인사이트 코포레이션 Condensed imidazole derivatives substituted with a tertiary hydroxyl group as PI3K-gamma inhibitors
CR20250050A (en) 2018-09-05 2025-03-19 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
MX2021003904A (en) 2018-10-05 2021-10-26 Annapurna Bio Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY.
CN112341450B (en) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 Immunomodulator
CN112341451B (en) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 Immunomodulator
CA3165339A1 (en) * 2019-12-19 2021-06-24 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Cd206 modulators their use and methods for preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (en) * 1993-09-09 1995-03-16 Schering Ag New benzimidazole derivatives, processes for their preparation and their pharmaceutical use
EE05515B1 (en) * 2000-01-14 2012-02-15 Schering@Aktiengesellschaft 1 2 diar 1-benzimidazoles for the treatment of diseases associated with microglial activation
DE10134775A1 (en) * 2001-07-06 2003-01-30 Schering Ag 1-alkyl-2.aryl-benzimidazole derivatives, their use for the manufacture of medicaments and pharmaceutical preparations containing these derivatives
DE10135050A1 (en) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
JP2005522447A (en) 2005-07-28
AU2003245523A1 (en) 2003-09-04
RS71304A (en) 2006-10-27
UA81111C2 (en) 2007-12-10
ZA200407382B (en) 2005-09-14
AR039556A1 (en) 2005-02-23
TW200306823A (en) 2003-12-01
NO20043840L (en) 2004-11-12
DE10207843A1 (en) 2003-09-04
KR20040084909A (en) 2004-10-06
BR0307706A (en) 2005-01-11
PE20030906A1 (en) 2004-01-17
CA2475770A1 (en) 2003-08-21
WO2003068225A1 (en) 2003-08-21
PL371327A1 (en) 2005-06-13
UY27662A1 (en) 2003-09-30
MXPA04007943A (en) 2004-11-26
EP1474138A1 (en) 2004-11-10
RU2004127677A (en) 2005-06-10
CN1756546A (en) 2006-04-05

Similar Documents

Publication Publication Date Title
ECSP045297A (en) MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFN?
BR0208636A (en) Therapeutic agent for chronic arthritic diseases of childhood-related diseases
DE60332358D1 (en) PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
ES2246567T3 (en) COMPOSITIONS FOR INHIBITING RECEPTORS OF T-CELLS AND USES OF THE SAME.
CR7875A (en) IMMUNOGLOBIN VARIANTS AND USES OF THIS
CL2008002207A1 (en) Pharmaceutical composition comprising immunosuppressants to improve the effect in the use of an antagonist of interleukin-6 (il-6) for the treatment of illnesses related to il-6 (div. Sol. 896-04).
UY27720A1 (en) MONOCYCLIC AROILPIRIDINONES,
AR005703A1 (en) SUBSTITUTED OXAZOLIDINONES, PROCEDURE FOR THE PREPARATION, USE OF THE SAME TO PREPARE MEDICINES AND MEDICINES THAT CONTAIN THEM
MX9400166A (en) VEGETABLE PROTEIN MICROSPHERES, HYDROLYZED, MODIFIED AND METHODS FOR THEIR PREPARATION AND USE.
UY28080A1 (en) POSITIONAL ISOMERS OF IFN PEG ALFA 2A
UY26370A1 (en) "IMIDAZO-5-IL-AMICAS BICÍCLICAS, DRUGS CONTAINING THEM, THEIR USE FOR THE PREPARATION OF DRUGS AND PROCEDURE FOR THE PREPARATION".
ES2192839T3 (en) TIMOSINA BETA 4 OXIDADA.
ATE213952T1 (en) RELEASE AND MOBILIZATION OF HEMATOPOIETIC CELLS
NO20044898L (en) New etonogestrel esters
DE60041655D1 (en) TRIGGERING RECEPTOR INVOLVED IN NATURAL CYTOTOXICITY OF NATURAL KILLER CELLS AND ANTIBODIES IDENTIFYING THIS RECEPTOR
EP1578373A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE IMMUNE SYSTEM
PT1017667E (en) 2-AMINO-6-METHYL-7-ACETYL-TETRALINE AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND / OR AUTOIMAL NATURE PATOLOGIES
UY27312A1 (en) NEW HETEROCICLOS 3
ATE431742T1 (en) MODIFIED CYTOKINE FOR CANCER THERAPY
CR7441A (en) MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY
UY26945A1 (en) PHENOXYPHENYL ALCANOSULPHONATES
ECSP045296A (en) DERIVATIVES OF BENZIMIDAZOL 1-FENIL-2-HETEROARIL-SUBSTITUTES, ITS USE TO PREPARE MEDICATIONS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES
DK1107779T3 (en) Drugs for Minipulation of T-Cell Immune Response
ES2188538T3 (en) USE OF 15-DEOXIPERGUALINE FOR THE TREATMENT OF HYPERREACTIVE INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES.
MD2053C2 (en) Remedy with interferon inducing action